Skip to content

Home Map The News Technology Politics Business Sports Entertainment

Global AI-Powered News Intelligence. Real-time headlines, mapped by continent and country, from authoritative sources worldwide.

Powered by AI

Navigate

Home
Map The News
About
Search

Sections

Technology
Politics
Business
Sports
Entertainment

More

Privacy
Contact
Sitemap
Robots

© 2026 newsGlobal. All rights reserved.

Headlines refresh every 10 minutes.

Home Map Search Topics About

Home / Business

AbbVie would gain an experimental eczema drug by buying biotech: report

MarketWatch

BusinessMarketWatch·Jun 20, 2026·1 min read

AbbVie would gain an experimental eczema drug by buying biotech: report

AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.

View original source — MarketWatch ↗

ShareShare on X Share on Facebook

Related stories

GSK Agrees to Buy Nuvalent for $10.6 Billion

BusinessJun 9, 2026 · 1 min

GSK Agrees to Buy Nuvalent for $10.6 Billion

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

Financial Times

BusinessJun 9, 2026 · 1 min

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

Financial Times

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

BusinessJun 9, 2026 · 1 min

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics

Financial Times

BusinessJun 19, 2026 · 1 min

AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics

Financial Times